Psychedelic medicine (New Rochelle, N.Y.)最新文献

{"title":"Psychedelic Medicine's Future Depends on Proactive Development of a Robust Medical Billing and Coding Strategy.","authors":"Brian S Barnett, Andrey Ostrovsky","doi":"10.1089/psymed.2022.0005","DOIUrl":"10.1089/psymed.2022.0005","url":null,"abstract":"<p><strong>Background: </strong>Although still investigational, psychedelic therapies appear poised to begin securing regulatory approval as medical treatments in the United States within the next 2 years. If approved, one of the most daunting barriers to equitable patient access to these novel treatments is their incorporation into the medical billing and coding system. Since specific billing codes for psychedelic therapy delivery do not exist, modification of existing codes or development of <i>de novo</i> codes will be necessary. This reality has created uncertainty about reimbursement and the financial future of psychedelic medicine.</p><p><strong>Opinion: </strong>We argue that development of <i>de novo</i> billing codes in conjunction with the American Medical Association's Current Procedural Terminology (CPT) Editorial Panel is the best approach for addressing psychedelic therapy reimbursement concerns. However, with no similar existing medical services to guide development, the potential need for multiple providers during dosing sessions, limited mental health care representation on the CPT Editorial Panel, and a number of misconceptions surrounding psychedelic therapy among critics, psychedelic therapy is particularly vulnerable to development of billing codes that undervalue the complexity of its delivery. With an industry-sponsored application for new CPT codes for \"psychedelic drug monitoring services\" soon to be reviewed by the CPT Editorial Panel, a critical step toward maximizing psychedelic therapy's societal impact has been taken. However, many questions remain about whether these proposed codes will provide adequate flexibility for a treatment modality involving various drugs, therapeutic approaches, and patient monitoring strategies, as well as which types of providers will qualify to use them. Whether these proposed codes ultimately become the bedrock of billing for psychedelic therapy or future codes are developed to augment or replace them is not known, but it is a promising sign that efforts to create a robust medical billing and coding strategy for psychedelic medicine are now underway.</p>","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"1 1","pages":"14-17"},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11658654/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88989410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proposed Consensus Statement on Defining Psychedelic Drugs.","authors":"David E Nichols, Charles D Nichols, Peter S Hendricks","doi":"10.1089/psymed.2022.0008","DOIUrl":"10.1089/psymed.2022.0008","url":null,"abstract":"","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"17 1","pages":"12-13"},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11658642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85984741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression.","authors":"Sandeep M Nayak, Bilal A Bari, David B Yaden, Meg J Spriggs, Fernando E Rosas, Joseph M Peill, Bruna Giribaldi, David Erritzoe, David J Nutt, Robin Carhart-Harris","doi":"10.1089/psymed.2022.0002","DOIUrl":"10.1089/psymed.2022.0002","url":null,"abstract":"<p><strong>Objectives: </strong>To perform a Bayesian reanalysis of a recent trial of psilocybin (COMP360) versus escitalopram for Major Depressive Disorder (MDD) in order to provide a more informative interpretation of the indeterminate outcome of a previous frequentist analysis.</p><p><strong>Design: </strong>Reanalysis of a two-arm double-blind placebo controlled trial.</p><p><strong>Participants: </strong>Fifty-nine patients with MDD.</p><p><strong>Interventions: </strong>Two doses of psilocybin 25mg and daily oral placebo versus daily escitalopram and 2 doses of psilocybin 1mg, with psychological support for both groups.</p><p><strong>Outcome measures: </strong>Quick Inventory of Depressive Symptomatology-Self-Report (QIDS SR-16), and three other depression scales as secondary outcomes: HAMD-17, MADRS, and BDI-1A.</p><p><strong>Results: </strong>Using Bayes factors and 'skeptical priors' which bias estimates towards zero, for the hypothesis that psilocybin is superior by any margin, we found indeterminate evidence for QIDS SR-16, strong evidence for BDI-1A and MADRS, and extremely strong evidence for HAMD-17. For the stronger hypothesis that psilocybin is superior by a 'clinically meaningful amount' (using literature defined values of the minimally clinically important difference), we found moderate evidence against it for QIDS SR-16, indeterminate evidence for BDI-1A and MADRS, and moderate evidence supporting it for HAMD-17. Furthermore, across the board we found extremely strong evidence for psilocybin's non-inferiority versus escitalopram. These findings were robust to prior sensitivity analysis.</p><p><strong>Conclusions: </strong>This Bayesian reanalysis supports the following inferences: 1) that psilocybin did indeed outperform escitalopram in this trial, but not to an extent that was clinically meaningful--and 2) that psilocybin is almost certainly non-inferior to escitalopram. The present results provide a more precise and nuanced interpretation to previously reported results from this trial, and support the need for further research into the relative efficacy of psilocybin therapy for depression with respect to current leading treatments.</p><p><strong>Trial registration number: </strong>NCT03429075.</p>","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"1 1","pages":"18-26"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278160/pdf/nihms-1904017.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10066275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dedication","authors":"","doi":"10.1089/psymed.2022.0000.ded","DOIUrl":"https://doi.org/10.1089/psymed.2022.0000.ded","url":null,"abstract":"Psychedelic MedicineVol. 1, No. 1 DedicationPublished Online:13 Mar 2023https://doi.org/10.1089/psymed.2022.0000.dedAboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View article\"Dedication.\" Psychedelic Medicine, 1(1), p. iFiguresReferencesRelatedDetails Volume 1Issue 1Mar 2023 InformationCopyright 2023, Mary Ann Liebert, Inc., publishersTo cite this article:Dedication.Psychedelic Medicine.Mar 2023.i-i.http://doi.org/10.1089/psymed.2022.0000.dedPublished in Volume: 1 Issue 1: March 13, 2023Online Ahead of Print:November 7, 2022PDF download","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"81 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136132085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lysergic Acid Diethylamide Alters the Effects of Brain Stimulation in Rodents","authors":"Lucas Dwiel, Angela Henricks, Elise Bragg, Jeff Nicol, Jiang Gui, Wilder Doucette","doi":"10.1089/psymed.2022.0014","DOIUrl":"https://doi.org/10.1089/psymed.2022.0014","url":null,"abstract":"Background: Psychedelic drugs have resurged in neuroscience and psychiatry with promising success in psychedelic-assisted therapy for the treatment of anxiety, depression, and addiction. At the cellular level, psychedelic drugs elicit neuroplastic processes 24 h after administration, priming neural circuits for change. The acute effects of psychedelic drugs are well characterized with functional imaging and neural oscillations showing an increase in the entropy of spontaneous cortical activity. Hypotheses: We hypothesized that cortical–striatal oscillations recorded in rats would confirm the effects of psychedelic drugs. We also hypothesized that brain stimulation delivered 24 h after lysergic acid diethylamide (LSD) administration would lead to different effects than brain stimulation alone. Methods: We recorded local field potential oscillations from rats after LSD or saline (SAL) administration and determined whether exposure to these treatments altered the effect of a targeted intervention (brain stimulation) 24 h later. Results: We confirmed acutely decreased low frequency power across the brain when rats are given LSD. We also demonstrated these altered states return to baseline after 24 h. Brain stimulation applied in the previously reported window of heightened neuroplasticity produced distinct shifts in brain state compared with brain stimulation applied 24 h after SAL administration. Conclusions: Despite the acute effects of LSD disappearing after 24 h, there are still latent effects that interact with brain stimulation to create larger and distinct changes in brain activity compared with brain stimulation alone. Our proof-of-concept findings are the first to suggest that psychedelic drugs could work in combination with brain stimulation to achieve enhanced effects on brain activity and future study will assess impacts on stimulation-induced changes in behavior.","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136181531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}